Compare Angi Inc (ANGI) vs Biogen Inc (BIIB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Angi Inc vs Biogen Inc — how do they compare? Angi Inc trades at $6.18 (market cap $252.19M), while Biogen Inc trades at $203.64 (market cap $29.40B). The key difference: Biogen Inc is far larger — about 116.6× Angi Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Angi Inc nearer its low. Which is the better fit depends on your goals.
| ANGI | BIIB | |
|---|---|---|
Market Cap | $252.19M | $29.40B |
Sector | Media | Health |
52-Week High | $18.90 | $216.63 |
52-Week Low | $4.78 | $122.68 |
Enterprise Value | $479.00M | $31.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ANGI trades at $6.24, down 1.89% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue of $1.03B in 2025 and net income of $43.83M, representing a 4.25% margin. Valuation metrics appear attractive with P/E of 14.85 and P/S of 0.27. Recent earnings showed a beat in Q1 2026 but misses in previous quarters, while analyst consensus price target sits at $9.20 with 33% buy ratings.
The stock presents a mixed outlook with attractive valuation multiples offset by declining revenue trends and ongoing legal investigations. Upside potential exists if the company's AI transition strategy succeeds, but risks include deteriorating core business metrics and multiple fraud investigations that could pressure shareholder value in the near term.
Biogen (BIIB) trades at $199.15, up 0.12% on the day, with a bullish technical signal from moving averages and RSI near oversold levels at 20.73. The company reported Q1 2026 EPS of $3.57, beating estimates of $3.05, continuing a trend of earnings surprises. Revenue for 2025 was $9.89B with a net income margin of 13.81%, while recent acquisitions like RayThera for up to $1B aim to bolster its immunology pipeline. Analyst consensus price target is $226.00, implying potential upside from current levels.
BIIB presents a mixed outlook with strong earnings momentum and strategic acquisitions offset by legacy drug sales declines and legal investigations. The stock's valuation at a P/E of 21.41 is reasonable relative to growth prospects, but investors face risks from pipeline execution and competitive pressures in biotech. Near-term catalysts include Alzheimer's data presentations at AAIC 2026 in July.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Angi Inc
Angi Inc connects quality home service professionals across different categories, from repairing and remodeling to cleaning and landscaping, with consumers. It has two geographical segments namely North America (the United States and Canada), which primarily includes the operations HomeAdvisor, Angie's List, Handy, mHelpDesk, HomeStars, and Fixd Repair
Read more on ANGI →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
